Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
18
03
2022
accepted:
05
08
2022
revised:
02
08
2022
pubmed:
13
10
2022
medline:
11
11
2022
entrez:
12
10
2022
Statut:
ppublish
Résumé
Patients living with cancer are at a significantly increased risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This systematic review aims to investigate the current available evidence about the immunogenicity of SARS-CoV-2 booster vaccines in patients living with cancer. A systematic search was undertaken for studies published until March 1, 2022. A systematic narrative review was undertaken to include all studies that evaluated the efficacy of booster vaccines against SARS-CoV-2 in patients with cancer. Fifteen studies encompassing 1205 patients with cancer were included. We found that a booster vaccine dose induced a higher response in patients with solid cancer as compared to haematological malignancies. Recent systemic anticancer therapy does not appear to affect seroconversion in solid organ malignancies, however, there is an association between B-cell depleting therapies and poor seroconversion in haematological patients. Third booster vaccination induces an improved antibody response to SARS-CoV-2 in adults with haematological and solid cancer, relative to patients who only receive two doses. Access to vaccination boosters should be made available to patients at risk of poor immunological responses, and the provision of fourth doses may be of benefit to this vulnerable population. PROSPERO number CRD42021270420.
Sections du résumé
BACKGROUND
Patients living with cancer are at a significantly increased risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This systematic review aims to investigate the current available evidence about the immunogenicity of SARS-CoV-2 booster vaccines in patients living with cancer.
METHODS
A systematic search was undertaken for studies published until March 1, 2022. A systematic narrative review was undertaken to include all studies that evaluated the efficacy of booster vaccines against SARS-CoV-2 in patients with cancer.
RESULTS
Fifteen studies encompassing 1205 patients with cancer were included. We found that a booster vaccine dose induced a higher response in patients with solid cancer as compared to haematological malignancies. Recent systemic anticancer therapy does not appear to affect seroconversion in solid organ malignancies, however, there is an association between B-cell depleting therapies and poor seroconversion in haematological patients.
CONCLUSIONS
Third booster vaccination induces an improved antibody response to SARS-CoV-2 in adults with haematological and solid cancer, relative to patients who only receive two doses. Access to vaccination boosters should be made available to patients at risk of poor immunological responses, and the provision of fourth doses may be of benefit to this vulnerable population.
REGISTRATION
PROSPERO number CRD42021270420.
Identifiants
pubmed: 36224402
doi: 10.1038/s41416-022-01951-y
pii: 10.1038/s41416-022-01951-y
pmc: PMC9555704
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1827-1836Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
World Health Organisation. Coronavirus disease (COVID-19) pandemic. World Health Organisation. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.
doi: 10.1016/S0140-6736(20)31187-9
pubmed: 32473681
pmcid: 7255743
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
doi: 10.1038/s41586-020-2521-4
pubmed: 32640463
pmcid: 7611074
Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer. 2020;139:181–7.
Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer. 2020;141:62–81.
doi: 10.1016/j.ejca.2020.09.035
pubmed: 33129039
pmcid: 7543792
de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel FWPJ, et al. Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–84.
doi: 10.1016/j.ejca.2020.09.027
pubmed: 33161241
pmcid: 7540213
Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50.
doi: 10.1016/j.ejca.2020.08.011
pubmed: 32971510
pmcid: 7467090
Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020;141:92–104.
doi: 10.1016/j.ejca.2020.09.028
pubmed: 33130550
pmcid: 7538140
Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–22.
doi: 10.1016/S1470-2045(20)30314-4
pubmed: 32539942
pmcid: 7292610
Várnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, et al. Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Netw Open. 2022;5:e220130.
doi: 10.1001/jamanetworkopen.2022.0130
pubmed: 35188551
pmcid: 8861846
Booth S, Curley HM, Varnai C, Arnold R, Lee LY, Campton NA, et al. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br J Haematol. 2022;196:892–901.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577 .
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
doi: 10.1016/S0140-6736(20)32661-1
pubmed: 33306989
pmcid: 7723445
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl J Med. 2021;384:403–16. https://doi.org/10.1056/NEJMoa2035389 .
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, et al. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Ann Oncol. 2022;33:158–68.
doi: 10.1016/j.annonc.2021.10.014
pubmed: 34718117
Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Gutiérrez T, Tagliamento M, et al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;160:243–60.
Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol. 2022;15:15 https://doi.org/10.1016/S0140-6736(20)30211-7 .
doi: 10.1016/S0140-6736(20)30211-7
pubmed: 35123511
pmcid: 8817639
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–76.
doi: 10.1016/S0140-6736(21)02717-3
pubmed: 34863358
pmcid: 8639161
Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020. GOV.UK. 2022. https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020
CDC. COVID-19 vaccines for moderately or severely immunocompromised people. Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632.
doi: 10.1136/bmj-2021-068632
pubmed: 35236664
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Yang LM, Costales C, Ramanathan M, Bulterys PL, Murugesan K, Schroers-Martin J, et al. Cell-mediated and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients [Internet]. bioRxiv:2022.01.04.22268750 [Preprint]. 2022 [cited 2022 Mar 2]. Available from: https://www.medrxiv.org/content/10.1101/2022.01.04.22268750v1
National Institutes of Health. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014. https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort .
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022;40:114–6.
doi: 10.1016/j.ccell.2021.12.013
pubmed: 34968417
Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40:3–5.
doi: 10.1016/j.ccell.2021.11.006
pubmed: 34838186
Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, et al. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response. Br J Haematol. 2022;196:577–84. https://doi.org/10.1111/bjh.17982 .
doi: 10.1111/bjh.17982
pubmed: 34872162
Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96:1195–203.
doi: 10.1002/ajh.26284
pubmed: 34185336
pmcid: 8420332
Bagacean C, Letestu R, Al-Nawakil C, Brichler S, Lévy V, Sritharan N, et al. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:207–11.
doi: 10.1182/bloodadvances.2021006215
pubmed: 34844264
pmcid: 8632355
Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031–3.
doi: 10.1016/j.ccell.2021.07.012
pubmed: 34331856
pmcid: 8295014
Marlet J, Gatault P, Maakaroun Z, Longuet H, Stefic K, Handala L, et al. Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia. Vaccines. 2021;9:1055.
doi: 10.3390/vaccines9101055
pubmed: 34696163
pmcid: 8539204
Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139:678–85.
doi: 10.1182/blood.2021014085
pubmed: 34861036
pmcid: 8648353
Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre JD, Gallien S, et al. SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 2022; https://jamanetwork.com/journals/jamaoncology/article-abstract/2788011
Rottenberg Y, Grinshpun A, Ben-Dov IZ, Oiknine Djian E, Wolf DG, Kadouri L. Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. 2022;8:300–1.
doi: 10.1001/jamaoncol.2021.6764
pubmed: 34812840
Zeng C, Evans JP, Chakravarthy K, Qu P, Reisinger S, Song NS, et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. 2022;40:117–9.
doi: 10.1016/j.ccell.2021.12.014
pubmed: 34986328
Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, et al. Efficacy of severe acute respiratory syndrome Coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17:239–51.
doi: 10.1016/j.jtho.2021.10.015
pubmed: 34798306
Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27:2002–11.
doi: 10.1038/s41591-021-01542-z
pubmed: 34594036
pmcid: 9004706
Di Noia V, Pimpinelli F, Renna D, Maccallini MT, Gariazzo L, Riva F, et al. Potentiation of humoral response to BNT162b2 vaccine after the third dose in patients with solid cancer. Ann Oncol. 2022;33:563–5.
Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5:2624–43.
doi: 10.1182/bloodadvances.2021004629
pubmed: 34152403
pmcid: 8216656
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.
doi: 10.1200/JCO.1998.16.8.2825
pubmed: 9704735
Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73.
doi: 10.1182/blood.2021011568
pubmed: 33861303
pmcid: 8061088
Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, et al. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022;40:103–108.e2.
doi: 10.1016/j.ccell.2021.12.002
pubmed: 34990570
pmcid: 8730528
Xing K, Tu X-Y, Liu M, Liang Z-W, Chen J-N, Li J-J, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23:221–8.
pubmed: 33691913
Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–22.
doi: 10.1038/s41586-021-03739-1
pubmed: 34192737
pmcid: 8373615
Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022;386:340–50.
doi: 10.1056/NEJMoa2115481
pubmed: 35021002
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–11.
doi: 10.1038/s41591-021-01377-8
pubmed: 34002089
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022; https://doi.org/10.1056/NEJMoa2116414